Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location

NCT05839899 | Unknown Phase 3 FDA Drug

• 1 other identifier: 2023P000467
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Patients who seek medication abortion early in pregnancy may have an ultrasound that does not show a pregnancy in the uterus. This is known as a "pregnancy of unknown location". These patients most likely have a pregnancy in the uterus that is too early to be seen on ultrasound, but it is possible that the pregnancy is not seen inside the uterus because it is outside of the uterus, known as an ectopic pregnancy. Patients with ectopic pregnancies are at risk for serious complications, and the medications used for medication abortion may not end an ectopic pregnancy. Currently, at Planned Parenthood League of Massachusetts (PPLM), patients seeking medication abortion, including some patients with a pregnancy of unknown location, are given mifepristone to begin the medication abortion at the clinic and then one dose of misoprostol to take at home to cause the pregnancy to pass. However, research suggests that a second dose of misoprostol leads to a higher rate of completed abortion for certain patients. This research is being conducted to learn if two doses of the at-home misoprostol during the medication abortion process leads to a higher rate of completed abortion for patients with pregnancy of unknown location. In this study, all participants will receive mifepristone as they normally would. Then, participants will be randomly assigned to receive either one dose of misoprostol or two doses of misoprostol.

Conditions

Abortion

Outcome Measures

Primary Outcomes (3)

• Recruitment rates, to determine feasibility of recruitment

  Feasibility of recruitment will be assessed by the recruitment and refusal rates. The recruitment rate will be calculated by dividing the total number of participants recruited by the number of months spent for recruitment.

  1 year

• Acceptability of second dose of misoprostol

  Acceptability of this regimen will be assessed by measuring how often patients assigned to the treatment arm actually take the second dose of misoprostol. If 13 or more patients in the double-miso group (\>50%) do not take the second dose, this will be considered unacceptable.

  1 month per subject, 1 year for all subjects

• Refusal rates, to determine feasibility of recruitment

  Feasibility recruitment will be assessed by the recruitment and refusal rates. The refusal rate will be calculated by dividing the total number of participants recruited by the number of patients approached for study participation..

  1 year

Study Arms (2)

Mifepristone plus Single dose misoprostol

ACTIVE COMPARATOR

Participant will take mifepristone, then one dose of misoprostol at home to pass the pregnancy (current routine abortion care).

Drug: Mifepristone plus one dose Misoprostol

Mifepristone plus two doses misoprostol

EXPERIMENTAL

Participant will take mifepristone, then at home will take two doses of misoprostol 4 hours apart to pass the pregnancy.

Drug: Mifepristone plus two doses Misoprostol

Interventions

Mifepristone plus one dose Misoprostol DRUG

Mifepristone 200mg PO, then 800 mcg of misoprostol 24-30 hours later

Mifepristone plus Single dose misoprostol

Mifepristone plus two doses Misoprostol DRUG

Mifepristone 200mg PO, then 800 mcg misoprostol 24-30 hours later, then another 800 mcg misoprostol 4 hours after that

Mifepristone plus two doses misoprostol

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Positive urine or serum hCG test
• No evidence of gestational sac on transvaginal ultrasound
• No evidence of ectopic pregnancy on transvaginal ultrasound
• Desire for same-day start medication abortion as method of pregnancy termination
• Eligible for same-day-start medication abortion based on PPLM clinical guidelines at the time of enrollment
• English-speaking

You may not qualify if:

• Ineligible for medication abortion at PPLM based on current PPLM clinical guidelines at the time of enrollment
• o PPLM clinical guidelines for medication abortion currently exclude those with chronic adrenal failure, concurrent long-term corticosteroid use, hemorrhagic disorders or concurrent anti-coagulation, porphyria, allergies to mifepristone or misoprostol, or an IUD in place.
• Ineligible for same-day-start medication abortion with PUL based on PPLM clinical guidelines and clinician assessment at the time of enrollment
• o PPLM clinical guidelines for initiating medication abortion with PUL currently exclude those with major ectopic risk factors (IUD in situ, prior ectopic, history of tubal surgery) or symptoms concerning for ectopic (i.e. pain, bleeding) per clinician discretion.
• Age less than 18 years old
• Prior participation in this study
• Anticipated inability to adhere to follow up protocol or complete the survey
• Unable to give informed consent or to complete all study procedures

Sponsors & Collaborators

• Planned Parenthood League of Massachusetts: lead

Study Sites (1)

Planned Parenthood League of Massachusetts

Boston, Massachusetts, 02215, United States

RECRUITING

MeSH Terms

Interventions

Mifepristone; Misoprostol

Intervention Hierarchy (Ancestors)

Estrenes; Estranes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Prostaglandins E, Synthetic; Prostaglandins, Synthetic; Prostaglandins; Eicosanoids; Fatty Acids, Unsaturated; Fatty Acids; Lipids; Autacoids; Inflammation Mediators; Biological Factors

Central Study Contacts

Director Research Ops

CONTACT

6176161600; research@pplm.org

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 4, 2023
• First Posted: May 3, 2023
• Study Start: August 30, 2023
• Primary Completion: July 1, 2024
• Study Completion: September 1, 2024
• Last Updated: September 5, 2023

Record last verified: 2023-08

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)